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ORIGINAL ARTICLEDevelopment and Validation of an
Algorithm to Accurately Identify Atopic
Eczema Patients in Primary Care Electronic
Health Records from the UK
Katrina Abuabara1, Alexa M. Magyari2, Ole Hoffstad3, Zarif K. Jabbar-Lopez4, Liam Smeeth5,
Hywel C. Williams6, Joel M. Gelfand3,7, David J. Margolis3,7 and Sinead M. Langan5Electronic health records hold great promise for clinical and epidemiologic research. Undertaking atopic
eczema (AE) research using such data is challenging because of its episodic and heterogeneous nature. We
sought to develop and validate a diagnostic algorithm that identifies AE cases based on codes used for elec-
tronic records used in the UK Health Improvement Network. We found that at least one of five diagnosis codes
plus two treatment codes for any skin-directed therapy were likely to accurately identify patients with AE. To
validate this algorithm, a questionnaire was sent to the physicians of 200 randomly selected children and adults.
The primary outcome, positive predictive value for a physician-confirmed diagnosis of AE, was 86% (95%
confidence interval ¼ 80e91). Additional criteria increased the PPV up to 95% but would miss up to 89% of
individuals with physician-confirmed AE. The first and last entered diagnosis codes for individuals showed
good agreement with the physician-confirmed age at onset and last disease activity; the mean difference was 0.8
years (95% confidence interval ¼ e0.3 to 1.9) and e1.3 years (95% confidence interval ¼ e2.5 to e0.1),
respectively. A combination of diagnostic and prescription codes can be used to reliably estimate the diagnosis
and duration of AE from The Health Improvement Network primary care electronic health records in the UK.
Journal of Investigative Dermatology (2017) 137, 1655e1662; doi:10.1016/j.jid.2017.03.029INTRODUCTION
Atopic eczema (AE, synonymous with atopic dermatitis and
commonly referred to as eczema) is one of the 50 most
burdensome diseases worldwide (Vos et al., 2012, Weidinger
and Novak, 2016). Therefore, there is great interest in un-
derstanding its causes, natural history, and potential associ-
ations with comorbid conditions. However, most studies rely
on highly selected specialty clinic populations, cross-
sectional studies, or self-reported data and are prone to bias
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dated diagnoses and longitudinal follow-up are needed.
Electronic health data from primary care practices in the
UK present an opportunity to directly address many of the
unanswered questions about long-term outcomes in AE in
particular. They are representative of the general population,
include relatively long-term follow-up of both children and
adults, and are appropriate for the study of AE because 97%
of patients are managed by general practitioners in the UK
(Emerson et al., 1998; Schofield et al., 2009). However, these
data were created for administrative and clinical purposes,
not designed specifically for research, and it is therefore
critically important that the validity of AE diagnoses in these
data sources is understood (Manuel et al., 2010). Because AE
is a heterogeneous and episodic condition with nonspecific
terminology, there exists high potential for misclassification
of diagnosis and duration of disease. There is no single
diagnostic test for AE, and it can be challenging to diagnose
in population-based studies because of its variability in
morphology, distribution, and periodicity. The diagnosis re-
lies on clinical judgment based on a combination of history
and physical examination. Previous studies using UK primary
care data to identify patients with AE report wide variations in
prevalence from 0e38% based on the coding algorithm used
(Anandan et al., 2009; Carey et al., 2003; McKeever et al.,
2001, 2002, 2004; Punekar and Sheikh, 2009; Simpson
et al., 2002, 2009). Moreover, there is some evidence that
chronic diseases, such as AE, may be more poorly recorded
over time in UK general practice data, because general
practitioners are not required to enter codes on eachestigative Dermatology. www.jidonline.org 1655
Table 1. Distribution of codes in the entire THIN database, %
Codes
Total Children (Ages 0e17)1 Adults (Ages 18D)1
N [ 9,775,618 n [ 1,404,158 n [ 8,371,460
Diagnosis codes
AD/eczema M111.00 6 13 5
Infantile eczema M112.00 1 7 0
Flexural eczema M113.00 1 2 0
Allergic/intrinsic eczema M114.00 0 0 0
Eczema not otherwise specified M12z100 6 8 6
One or more of the five codes listed above 13 23 11
Two or more of the five codes listed above 4 10 4
One or more of 32 likely eczema codes2 14 25 13
One or more of 74 possible eczema codes2 29 47 26
Prescription codes
One or more prescription for any AD-related therapy3 45 57 42
One or more prescription for a topical steroid or calcineurin inhibitor3 39 42 38
One or more prescription for an AD-related systemic treatment3 1 0 1
Other codes
One or more exclusionary condition4 7 3 8
One or more dermatology consult code 4 2 5
One or more biopsy or patch testing code 1 0 1
Abbreviation: AD, atopic dermatitis.
1Ages as of January 2013; among adults, codes may have occurred before age 18 years.
2See Supplementary Table S1.
3Includes topical skin preparations, topical steroids, topical calcineurin inhibitors, topical anti-infective treatments, and systemic treatments (including
methotrexate, azathioprine, mycophenolate, cyclosporine, biologics, or phototherapy); see Supplementary Table S2.
4See Supplementary Table S3 online.
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1656occasion for chronic conditions (Jordan et al., 2004; Khan
et al., 2010).
This study aimed to enhance identification of patients with
AE within electronic health records. The objectives were to
develop and validate a diagnostic algorithm for AE that
identifies cases based on codes and, secondarily, to examine
the agreement between physician report and codes for AE
disease onset, duration, and severity.
RESULTS
Algorithm development
A list of potential AE diagnosis and treatment codes was
developed by using a keyword search and examining affiliated
codes (see Supplementary Table S1 online), and the five most
common and specific codes for AE were chosen to identify
those likely to have AE: M111.00 atopic dermatitis/eczema,
M1120.0 infantile eczema, M113.00 flexural eczema,
M11400 allergic/intrinsic eczema, and M12z100 eczema not
otherwise specified. When we examined the frequency of
medical codes among individual patients, we found that
including 32 codes likely to be related to AE rather than only
the five most common codes only slightly increased the
number of individuals identified but that including up to 74
possible AE codes nearly doubled the number of individuals
identified (Table 1). The distribution of some codes varied be-
tween children and adults; for example, M1120.0/infantile
eczema was more commonly used in children.
Despite the chronicity of AE, any of the five most common
diagnosis codes were rarely repeated in the database; overall,
patients had a mean of 1.2 (standard deviation ¼ 0.5) codes
during 5.6 years (standard deviation¼ 8.0) of follow-up. BecauseJournal of Investigative Dermatology (2017), Volume 137AE is by definition a chronic condition, it was important to
include more than one code in our algorithm, but requiring in-
dividuals to have two or more diagnosis codes would exclude
more than 80% of the potential AE population. Therefore, the
distribution of treatment codes was also examined. In the UK,
medical record codes and treatment codes can be entered
independently (i.e., a prescription code does not require an
associated diagnostic code). Prescriptions, including emollient
preparations, are available through the National Health Service,
so we examined prescription codes for all potential relevant
therapies including topical emollients, topical steroids, topical
calcineurin inhibitors, topical anti-infective treatments, and sys-
temic immunomodulatorymedications (includingmethotrexate,
azathioprine, mycophenolate, cyclosporine, or biologics) based
onBritishNational Formulary groupings andphototherapy codes
(Joint Formulary Committee, 2015) (see Supplementary Table S2
online). Because prescriptions are free of charge for children
only,we stratified our analyses byage (i.e., childrenyounger than
18 years vs. adults). We also specifically examined the use of
topical steroids and topical calcineurin inhibitors (which are
likely to be more specific for AE). To ensure that we captured
patients with chronic AE in our algorithm, we chose to include
patients with at least one of the five medical codes frequently
used for AE as listed and at least two treatment codes for any AE-
related therapy on separate dates (at any time point relative to the
AE diagnosis, because symptoms may precede the actual
diagnosis).
Physician survey
To validate the algorithm for AE, we surveyed the physicians
of a random sample of 100 children (<18 years of age) and
Figure 1. Flow chart showing the
sampling of patients from THIN and
resulting classification. *Any of the
five most commonly used Read codes
(atopic dermatitis/eczema M111.00,
infantile eczema M112.00, flexural
eczema M113.00, allergic/intrinsic
eczema M114.00, or eczema not
otherwise specified M12z100). **Any
code for topical emollients, topical
steroids, topical calcineurin inhibitors,
topical anti-infective treatments,
systemic immunomodulatory
medications (including methotrexate,
azathioprine, mycophenolate,
cyclosporine, or biologics) or
phototherapy on separate days; see
Supplementary Table S2). AIS,
Additional Information Services;
THIN, The Health Improvement
Network.
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(96% for adults and 97% for children), and there was no
significant difference in response rate by age or sex. The al-
gorithm for identifying patients with AE performed well, and
there were no significant differences in codes between those
with and without physician-confirmed AE (Table 2). The
positive predictive value (PPV) for a single diagnostic code
and at least two treatment codes was 86% overall (95%
confidence interval [CI] ¼ 80e91) and was higher among
children (90%) than adults (82%), although this difference
was not statistically significant (Pearson c2 ¼ 2.76, P ¼
0.097).
When we examined whether the use of more stringent
criteria would improve the prediction of physician-confirmed
AE, we found that adding additional criteria to the algorithm
had the potential to increase the PPV but would result in
smaller numbers of individuals being detected (Table 3). For
example, requiring two AE codes would increase the PPV to
91% but would detect only 83 of 163 (51%) of those with
physician-confirmed AE. Similarly, requiring a dermatology
consultation code in addition to the AE and prescription
codes would increase the PPV to 95% but would detect only
18 of 163 (11%) of those with physician-confirmed AE.
Requiring the prescriptions to be for medications more spe-
cific to AE (i.e., topical steroids or calcineurin inhibitors) did
not significantly change the PPV.
The average age of onset and oldest age of disease activity
requiring physician contact estimated using codes from the
database were similar to what physicians reported (Table 4).
The mean estimated ages at onset using the first diagnosis
code or the first treatment code were both slightly younger
than the physician estimate (mean difference ¼ 0.8 years,
95% CI ¼ e0.3 to 1.9 and mean difference ¼ 0.4 years, 95%
CI ¼ e0.8 to 1.7, respectively), and 76% of estimates were
within 1 year of each other. The mean estimated age at last
date of AE activity using the last diagnosis code or last
treatment code were both older than the physician estimate
(mean difference ¼ e1.3 years, 95% CI ¼ e2.5 to e0.1 and
mean difference ¼ e3.9 years, 95% CI ¼ e5.3 to e2.4,respectively), and 79% of estimates within 5 years of each
other. Bland-Altman plots for all estimates are shown in
Supplementary Figure S1 online. When we stratified these
estimates by age comparing children under age 18 years
versus adults we found similar results (see Supplementary
Table S4).
In our sample, 48 patients were reported by the physician
to have had symptoms in the year prior to their last visit, 27
(56%) of whom were assessed as having mild disease and 19
(40%) of who were assessed as having moderate disease
based on the severity descriptions in the National Institute for
Health and Care Excellence guidelines. Patients with mod-
erate disease had more treatment codes during that year than
patients with mild disease (median ¼ 5 vs. 2, P-value for two-
sample Wilcoxon rank sum test ¼ 0.887). None were re-
ported to have severe disease, limiting our ability to draw any
conclusions about the validity of medical record codes to
predict disease severity.
Finally, we assessed whether physicians would be able to
adequately respond to the UK Working Party criteria (origi-
nally designed for in-person assessment), enabling us to
compare a set of well-validated criteria for use in large
epidemiologic studies with our outcomes in routinely
collected electronic health data. For each question, we gave
physicians the option of choosing Don’t know. The high
number of uncertain responses resulted in poor ability to
discriminate between those with and without AE (see
Supplementary Table S5 online). We found that only 52
(32%) of those with physician-confirmed AE in our sample
met the criteria (an itchy skin condition plus at least three of
the following: flexural involvement, history of asthma/hay
fever, history of generalized dry skin, onset of rash at younger
than age 2 years, and visible flexural dermatitis).
DISCUSSION
Interpretation of main findings
Patients with AE were accurately identified if they had at least
one AE diagnostic code and at least two prescription codes
for AE-related treatments in a large electronic medical recordwww.jidonline.org 1657
Table 2. Survey sample characteristics
Survey Responses Total1 Confirmed Eczema1 No Eczema1
Chi-Square or Fisher’s
P-Value
All participants, n (%) 200 (100) 163 (81.5) 26 (13)
Diagnosis codes, n (%)
AD/eczema M111.00 116 (58) 98 (60) 13 (50) 0.330
Infantile eczema M112.00 30 (15) 24 (15) 4 (15) 0.930
Flexural eczema M113.00 16 (8) 13 (8) 2 (8) 0.960
Allergic/intrinsic eczema M114.00 3 (2) 3 (2) 0 (0) 0.486
Eczema not otherwise specified M12z100 86 (43) 73 (45) 9 (34) 0.331
Mean number (SD) of the five eczema codes listed above 1.3 (0.5) 1.3 (0.6) 1.1 (0.3) 0.051
Mean number (SD) of 32 likely eczema codes2 2.6 (2.9) 2.8 (3.1) 1.7 (1.2) 0.070
Mean number (SD) of 74 possible eczema codes2 4.0 (3.8) 4.1 (3.9) 3.2 (3.3) 0.271
Prescription codes
Mean number (SD) of prescriptions for any AD-related therapy3 16.3 (24.5) 17.5 (26) 11.1 (15.0) 0.226
Mean number (SD) of topical steroid or calcineurin inhibitor prescriptions3 9 (15) 6.6 (8.9) 6.5 (7.9) 0.953
Mean number (SD) of AD-related systemic treatment codes3 0.4 (5.8) 0.5 (6.4) 0 (0) 0.691
Other
Mean number (SD) of exclusionary diagnostic codes4 0.4 (1.7) 0.3 (0.7) 0.5 (1.6) 0.281
Total (%) with at least one exclusionary condition4 29 (15) 25 (15.3) 3 (11.5)
Mean number (SD) of diagnostic procedure (biopsy or patch testing) codes4 0 0 0 N/A
Mean number (SD) of dermatology consultation codes4 0.2 (1.1) 0.3 (1.6) 0.0 (0.2) 0.308
Total (%) with at least one dermatology consultation code 19 (10) 18 (11) 1 (4)
History of atopy, n (%)5 64 (39) 56 (41) 6 (24) 0.110
Male, n (%) 100 (50) 86 (53) 9 (35) 0.086
Abbreviation: AD, atopic dermatitis; N/A, not applicable; SD, standard deviation.
1Columns do not sum to 200 because of missing values (seven unreturned surveys and four returned surveys missing a response to the eczema question).
2See Supplementary Table S1.
3Includes topical skin preparations, topical steroids, topical calcineurin inhibitors, topical anti-infective treatments, and AD-related systemic treatments
(including methotrexate, azathioprine, mycophenolate, cyclosporine, biologics, or phototherapy); see Supplementary Table S2.
4See Supplementary Table S3.
5Per physician response on survey; defined as a history of other atopic disease (e.g., asthma or allergic rhinitis) for adults or a family history of atopic disease
in a first degree relative if aged under 4 years.
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The PPV, or probability that individuals identified by our al-
gorithm truly have the disease as determined by their doctors,
was 86%, which is similar to the PPV of coding algorithms for
other chronic diseases in routinely collected data (Khan et al.,
2010). The PPV was higher in children, but the algorithm still
performed well to identify adults with AE.
This study indicates that the types, number, and frequency
of codes used to identify AE patients in routinely collected
data are important because small differences have the po-
tential to cause substantial misclassification. After examining
the distribution of all codes potentially related to AE, we
chose to use the five most common AE codes in addition to
treatment codes for the primary algorithm. As shown in
Table 1, expanding the definition from five to 32 codes (likely
related to AE but rarely used) would have increased the
proportion of the population identified only from 13% to
14%, so we opted for the more parsimonious algorithm. In
contrast, using a single code to define AE, for example AD/
eczema (M111.00), would identify far fewer individuals (only
6% of the population). Although it was impractical and
prohibitively costly to sample enough physicians to calculate
the sensitivity, specificity, and predictive value of each of
these variations, we present the proportion of patients iden-
tified by each set of codes to illustrate the potential magni-
tude of misclassification. We were able to calculate post hocJournal of Investigative Dermatology (2017), Volume 137changes in the PPV caused by adding criteria to our algo-
rithm. Inclusion of a second diagnosis code, allergy code, or
consult code all increased the PPV but would have identified
far fewer patients. The ideal balance between these factors
depends on the research question. For example, an algorithm
with a very high PPV that captures only a fraction of those
with disease may be acceptable for a case-control study. On
the other hand, the ideal algorithm for a prevalence study
would aim to assess the total population burden accurately
and may include more patients with mild or marginal
disease.
Because AE is a chronic condition, we explored the pos-
sibility of using codes from more than one time point to
identify patients. In the UK, providers are not required to re-
enter codes for chronic conditions, and only 36% of in-
dividuals had more than one AE diagnosis code. Treatment
codes, which can be entered independently from diagnostic
codes, were used more frequently and were therefore
included in the algorithm. When selecting the treatments, we
opted for an inclusive approach and used all potential AE-
related treatments, even emollients, as listed under British
National Formulary categories. This approach may include
treatments not specifically for AE, so we examined the per-
formance of a more limited definition of treatments (only
topical steroids or topical calcineurin inhibitors) and found
that it did not change the PPV but would identify 4e18%
Table 3. Positive predictive value of coding algorithms
True
Positive/All
Positive
% of Patients with
Confirmed Eczema
Identified
All
Children
(Ages 0e17)
Adults (Ages
18D)
PPV,
%
95%
CI
PPV,
%
95%
CI
PPV,
%
95%
CI
Baseline algorithm; one of five eczema codes þ at least two
treatment codes on separate dates (survey selection criteria)
163/189 N/A 86 80e91 90 83e96 82 73e89
Alternative algorithms1
Baseline algorithm; at least one treatment is a topical steroid/TCI
code
157/183 96 86 80e91 90 81e95 82 73e89
Baseline algorithm; at least two treatments are topical steroid/TCI
codes
133/153 82 87 81e92 91 82e97 84 74e91
Baseline algorithm; at least one treatment is a topical steroid/TCI
code either 3 months before or up to 1 year after the eczema code
81/92 50 88 80e94 92 80e98 84 70e94
Baseline algorithm þ an additional eczema code (two eczema
codes total)
83/91 51 91 83e96 94 82e99 88 74e96
Baseline algorithm þ an additional eczema code (two eczema
codes total); at least one treatment is a topical steroid/TCI code
82/90 50 91 83e96 94 83e99 88 74e96
Baseline algorithm þ an additional eczema code (two eczema
codes total); at least two treatments are topical steroid/TCI code
133/153 82 87 81e92 91 82e97 84 74e91
Baseline algorithm þ no exclusionary condition code 138/161 85 86 79e91 89 81e95 82 71e90
Baseline algorithm þ asthma or rhinitis code 52/56 32 93 83e98 95 76e100 91 77e98
Baseline algorithm þ dermatology consult code 18/19 11 95 74e100 100 54e100 92 64e100
Abbreviations: CI, confidence interval; PPV, positive predictive value; TCI, topical calcineurin inhibitor.
1See Supplementary Tables S2 and S3 for lists of codes.
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of the five most common medical codes never received any
treatment codes. Our algorithm excluded these patients,
some of whom may have had mild untreated disease.
Because we randomly selected individuals with AE di-
agnoses at any time point, only a fraction had disease activity
during the year before their last visit, resulting in too few
numbers to meaningfully assess the validity of codes relative
to disease severity. Additional research is necessary to vali-
date whether codes can be used to ascertain severity and
disease flares in routinely collected data.
Comparability to other studies
Three other studies attempted to validate routinely collected
data for identifying individuals with AE. Two examined the
use of medications alone and found they had poor discrim-
inatory power to identify patients with AE in The Netherlands
and Sweden (Mulder et al., 2016; Ortqvist et al., 2013). The
distribution of treatment codes in our data, as shown in
Table 1, also suggested that the were not likely to selectively
identify patients with AD, which is why we designed our
algorithm to incorporate both diagnosis and treatment codes
as described above. The third study compared International
Classification of Diseases, Ninth Revision, codes from a ter-
tiary care population in the US with Hanifin and Rajka and
UK Working Party criteria found in the medical record and
found poor overlap (Hsu et al., 2016), possibly because of the
lack of standardized recording of specific diagnostic features
in the medical record. We assessed whether it was possible to
compare our results to the UK Working Party diagnostic
criteria, which have been used for epidemiological studies in
multiple international settings but were developed for in-
person assessment (Brenninkmeijer et al., 2008; Williams
et al., 1994). Because physicians responded Don’t know toso many of the UK Working Party questions in our survey, we
were unable to make meaningful comparisons. We hypoth-
esize that the high rates of uncertainty were because there
were not enough data in the medical record to enable phy-
sicians to answer all of the required questions and therefore
caution against using these as a criterion standard from
medical record review when they were not systematically
assessed. It is also possible that those deemed to have AE by
their physicians simply would not fulfill the criteria if they
had been ascertained fully, and further specially designed
studies are needed to test this notion.
Strengths and weaknesses
Strengths of our study include the use of diagnosis and
treatment codes, stratified sampling among children and
adults, a large representative database with longitudinal
follow-up, and physician confirmation of disease as the cri-
terion standard. We sampled general practice physicians
rather than dermatologists because 97% of patients with AE
are managed by general practitioners in the UK, and sam-
pling specialists would have limited the generalizability of
the results (Emerson et al., 1998; Schofield et al., 2009).
Ideally, patients would have been assessed in person to
confirm their diagnoses. Because this was not possible
through the Additional Information Services in THIN, we
queried their physicians instead. The physicians were asked
to assess the patient based on their recall and review of the
medical record. This approach was chosen over a medical
record review because it allowed for direct assessment as to
whether the physician really believed the patient had AE
(regardless of coding).
Our results are directly generalizable only to THIN,
although the algorithm is likely to perform similarly in the
other UK primary care databases that have substantialwww.jidonline.org 1659
Table 4. Age in years at diagnosis or at last disease activity requiring contact with the physician
Distribution of
Estimates by Source
Difference Between
Physician Estimate from
Survey and Database
Mean 95% CI Mean 95% CI
Age at diagnosis (n ¼ 160)
Physician survey 17.9 14.3e21.4 N/A N/A
Database
First diagnosis code1 17.1 13.5e20.6 0.8 e 0.3 to 1.9
First prescription for any eczema treatment2 17.4 13.9e21.0 0.4 e 0.8 to 1.7
If no symptoms in the year before the last visit date, age at last disease activity (n ¼ 53)
Physician survey 20.7 14.3e27.2 N/A N/A
Database
Last diagnosis code1 22.0 15.6e28.5 e1.3 e 2.5 to e0.1
Last prescription for any eczema treatment2 24.6 14.3e27.2 e3.9 e 5.3 to e2.4
Abbreviations: CI, confidence interval; N/A, not applicable.
1Any of the five most commonly used codes (atopic dermatitis/eczema M111.00, infantile eczema M112.00, flexural eczema M113.00, allergic/intrinsic
eczema M114.00, or eczema not otherwise specified M12z100).
2See Supplementary Table S2.
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www.cprd.com/] and other UK primary care data sources
including QResearch [http://www.qresearch.org/]). Valida-
tion studies are inherently context specific, and the PPV of
our algorithm may vary in settings where the prevalence of
AE and data structure differ. For example, we found that
adding a dermatology consultation code to our baseline al-
gorithm increased the PPV to 90% (95% CI ¼ 74e100)
(Table 3); however, it identified only 11% of the patients with
confirmed eczema because very few patients are referred to
specialists in the UK. In the US, where the proportion of
patients who are referred to a specialist is higher (it is esti-
mated 43% of pediatric AE visits were to generalists between
1997 and 2004) (Horii et al., 2007), adding a dermatology
consultation code to the baseline algorithm is likely to
identify a higher proportion of patients with confirmed AE. If
our algorithm were used in settings where patients do not
receive prescriptions for emollients or other topical prepa-
rations or anti-infective treatments, its performance may be
more comparable to the first two alternative algorithms listed
in Table 3, which are based on the use of topical steroids and
calcineurin inhibitors alone. We emphasize the importance
of carefully examining the distribution and types of codes
before undertaking a study using electronic medical record
data, and we present the distribution of categories of codes in
Table 1 so that researchers can evaluate how applicable our
results may be to their data.
Implications for future research
Validation studies that ensure patients are accurately identi-
fied are a high priority, to enable the use of increasingly
available and robust sources of routinely collected electronic
health data (De Coster et al., 2006), but they have not been
widely used in the AE literature to date. This study showed
that AE patients can be accurately identified in the UK THIN
database and that changes in the number, type, or frequency
of codes used could result in large differences in the number
of patients identified. Additional work is necessary to deter-
mine the PPV of our algorithm in other contexts. We highlightJournal of Investigative Dermatology (2017), Volume 137factors to consider when examining the frequency and dis-
tribution of diagnostic and treatment codes in any electronic
medical record database, which are important for researchers
to avoid misclassification bias. Efforts are underway to
determine how AE patients have been identified in published
studies using electronic health data (Dizon et al., 2016), and
we encourage the research community to work toward
developing standards for methodology and reporting to
improve comparability of studies and advance our under-
standing of AE.
METHODS
Study design
Our study consisted of two parts: a longitudinal cohort study to
develop a diagnostic algorithm and a physician survey to validate it.
We followed guidelines for reporting of validation studies and
reporting of studies conducted using observational routinely
collected health data (Benchimol et al., 2011, 2016).
Participants/data source
THIN is a database comprising the electronic health records of
people registered with participating general practices. THIN is
broadly representative of the general UK population in terms of age,
sex, ethnicity, and geography and is one of three major UK primary
care databases (Shephard et al., 2011). We chose this data source
because it is one of the world’s largest sources of anonymized lon-
gitudinal data from primary care practices, with over 85 million
patient-years of follow-up, and because we had institutional access
and experience using the data (Margolis et al., 2007, 2008; Ogdie
et al., 2015; Seminara et al., 2011). Previous validation studies
have shown that the recording is highly accurate and nearly com-
plete, and THIN has been used to study multiple chronic conditions.
Participating practices are remunerated for recording data on clinical
diagnoses, test results, prescriptions, and referral data via the Read/
Oxford Medical Information System coding framework, which is
based on the International Classification of Diseases coding system.
The raw data are updated monthly and undergo extensive quality
control and validity checks by a centralized research team before
release. Practices may choose to participate in the Additional In-
formation Services Program, which administers surveys to
K Abuabara et al.
Validation of Atopic Eczema in Electronic Health Recordsconsenting physician practices. Approximately 60% of all THIN
practices actively participated in this program when our survey was
administered in October 2015.
Algorithm development
A list of potential AE diagnosis and treatment codes were developed
by using a keyword search and examining affiliated codes (see
Supplementary Table S1). The distribution of codes was examined,
and in consultation with a panel of experts on AE epidemiology and
use of routinely collected data (HCW, DM, LS, SML, and KA) a
parsimonious algorithm was developed to identify patients most
likely to have AE.
Physician survey
The survey was sent to the physicians of a random sample of 100
children (<18 years of age) and 100 adults with acceptable records
who were alive and currently enrolled in practices participating in the
Additional Information Services (Figure 1). The primary outcome was
the PPV, or probability that subjects identified by the algorithm truly
have the disease, because this measure is the most relevant for
avoiding misclassification bias in subsequent studies of AE (Choi,
1992) (Supplementary Figure S2). Assuming a physician response
rate of 90% (based on prior studies using physician confirmation of
chronic disease in routinely collected data [Khan et al., 2010;
Seminara et al., 2011]), a sample of 200 patients should have
enabled us to obtain a 95% CI of 0.85e0.94 around an a priori
estimated PPV of 0.90. Given funding constraints, we chose to sample
only patients with codes suggestive of AE. Sampling additional sub-
jects without AE codes would have enabled us to also calculate
sensitivity and specificity of the algorithm.
A standardized letter was sent to each practice requesting comple-
tion of a 1-page survey (see Supplementary Figures S3 and S4 online),
and physicians received monthly reminders for completion and
compensation for their time. If the diagnosis of AE was confirmed, we
thenasked thephysician to (i) providea global assessmentof averageAE
severityover thepast 12months, (ii) confirm theageatAEonset, and (iii)
confirm whether the patient still has active AE or whether the patient’s
AE is in remission.Althoughmany eczema-specific severity scales have
been developed and validated for assessment of patient outcomes in
clinical trials, few are designed to address long-term severity (Schmitt
et al., 2007). Therefore, to assess severity, we used descriptions of
mild, moderate, and severe disease from the UK National Institute for
Health and Care Excellence guidelines for management of eczema
(National Institute for Health and Care Excellence, 2007). Finally, to
determinewhether our results could be comparedwith another widely
used definition of AE in large epidemiologic studies, the survey
included the UK Working Party refinement of Hanifin and Rajka’s
diagnostic criteria questions (Brenninkmeijer et al., 2008; Williams
et al., 1994).
AE is a clinical diagnosis, and biopsy and laboratory tests are
nonspecific; therefore, we relied on the physician’s confirmation of
the diagnosis as the criterion standard. This approach is consistent
with other validation studies of chronic conditions in medical record
databases in UK primary care databases (Ogdie et al., 2014;
Seminara et al., 2011; Soriano et al., 2001). Physicians were asked
to fill out the survey based on their knowledge of the patient and
review of his or her medical record.
Analysis
For the 200 patients whose physicians were surveyed, differences in
codes between those with and without physician-confirmed AE wereexamined, and the PPV of our algorithm for identifying AE patients
was calculated. The PPVs of alternative algorithms with additional
criteria for identifying patients with AE were also calculated. Next,
the age of disease onset and “remission” reported in the physician
survey were compared with dates calculated from the database us-
ing the first and last AE diagnosis and prescription codes. Agreement
was assessed descriptively using Bland-Altman plots (Bland and
Altman, 1986). All analyses were stratified by age (i.e., children
younger than 18 years vs. adults). Analyses were performed using
Stata, version 14 (Stata Corporation, College Station, TX).
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